GlassScriptPhysician profile
Gerald Clinton Lewis
NPI 1639279177
$335,706.26
in general payments reported to CMS, 2019-2025
40 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
See the full distribution for Psychiatric/Mental Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33K · 2022: $40K · 2023: $101K · 2024: $84K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $180K · Consulting Fee: $41K · Food and Beverage: $20K · Honoraria: $12K · Travel and Lodging: $8,878 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $179,605.50 |
| Consulting Fee | $41,007.50 |
| Food and Beverage | $20,409.76 |
| Honoraria | $12,352.00 |
| Travel and Lodging | $8,877.68 |
| Education | $283.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $131,172.10 | 2021-2025 | Ingrezza |
| Abbvie INC. | $59,375.38 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $55,205.72 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $40,664.69 | 2022-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $24,960.34 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Almatica Pharma LLC | $5,814.08 | 2021-2025 | Loreev Xr |
| Allergan, INC. | $3,575.00 | 2021 | |
| Corium, LLC | $2,305.14 | 2021-2025 | Azstarys, Adlarity, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,898.51 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,770.57 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,004.78 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Jazz Pharmaceuticals INC. | $845.45 | 2021-2025 | |
| Lundbeck LLC | $809.80 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $648.62 | 2021-2025 | Trintellix |
| Tris Pharma INC | $611.18 | 2022-2025 | Dyanavel Xr |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $530.83 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $522.02 | 2021-2025 | Fanapt |
| Avadel Cns Pharmaceuticals, LLC | $490.63 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $447.09 | 2022-2025 | Wakix |
| Noven Therapeutics, LLC | $421.36 | 2021-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $421.33 | 2021-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $355.26 | 2022-2025 | Quviviq, Quviviq |
| Bausch Health US, LLC | $303.88 | 2021-2025 | Wellbutrin, Aplenzin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $259.68 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $219.65 | 2021-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $160.66 | 2024-2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $160.34 | 2021-2025 | Subvenite, Lamotrigine |
| Neuronetics, INC. | $104.93 | 2023-2024 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $103.65 | 2025 | Jornay Pm |
| Biohaven Pharmaceuticals, INC. | $99.33 | 2021 | |
| Pfizer INC. | $95.61 | 2024-2025 | |
| Eisai INC. | $88.56 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $69.08 | 2022 | |
| Indivior INC. | $46.76 | 2022-2024 | Perseris, Sublocade |
| Noven Pharmaceuticals, INC. | $39.76 | 2021 | |
| Adlon Therapeutics L.P. | $39.15 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.92 | 2022 | |
| Braeburn INC. | $15.47 | 2024 | Brixadi |
| Alfasigma USA, INC. | $14.01 | 2022 | |
| Acadia Pharmaceuticals INC | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.